Ibio IncChange company Symbol lookupSelect an option...IBIO Ibio IncSPRC Scisparc LtdNRSN Neurosense Therapeutics LtdACNT Ascent Industries CoFATH Fathom Digital Manufacturing CorpPAYX Paychex IncWAVD Wavedancer IncRNXT RenovoRx IncGBNY Generations Bancorp NY IncPOL Polished.Com IncGo
iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.
|
|
|
|
| |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.